Hot Investor Mandate: VC Fund with Strategic Ties to a Large Corporation Seeks Disruptive Therapeutics, Diagnostics, and Life Science Tools Across the Globe

1 Jul

A VC fund in the USA is independently managed in a strategic partnership with a large corporation. The firm invests in early-stage disruptive life science tools, therapeutics, and diagnostic companies. Typical allocations range from $2-10 million initially in a Series A or B round and can be up to $15-20 million over the life span of the company. The firm seeks to syndicate with other leading institutional and strategic investors.  The firm expects to make 4-5 new investments over the next 12 months and considers opportunities globally with a focus in the US.

The firm is interested in areas where its expertise and special relationship with the parent corporation can add value. This includes therapeutics, clinical diagnostics, and life science tools. The firm focuses on applications of genomics including sequencing, assay development, agriculture and environmental science, industrial biotech, digital health, public safety and personal wellness, proteomics and other ‘omics’ areas. The firm prefers pre-revenue companies that have achieved proof-of-concept.

The firm seeks to work with experienced management teams with sector expertise. The firm’s team members have decades of entrepreneurial experience in genomics and may request a board seat depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: